This retrospective study compares the reconstitution of T, B and NK cells in three groups of patients transplanted for haematological malignancies with grafts from their HLAidentical sibling donors. In all, 15 patients received PBSC after a nonmyeloablative conditioning regimen consisting of fludarabine and 200 cGy TBI, 13 patients received PBSC after myeloablative conditioning and 37 patients received BM after myeloablative conditioning. In the nonmyeloablative group, the NK cells normalised after 1 month, the CD8+ T cells normalised after 3 months, the CD4+ T cells reached near normal values after 9 months and the B cell values were reduced until 12 months after transplant. In the two myeloablative groups, recipients of PBSC had a significantly higher number of CD4+ T cells after 4 months (P ¼ 0.004) and after 12 months (P ¼ 0.001), than recipients of BM. We found no differences in the T cell reconstitution between the two PBSC groups. This was of interest as the recipients of nonmyeloablative conditioning were older (Po0.001) and had a higher occurrence of chronic GVHD (Po0.05) than the recipients of myeloablative conditioning. In contrast, the recipients of nonmyeloablative conditioning had a delayed B cell recovery when compared to the patients who received myeloablative conditioning (P ¼ 0.04).
Summary:
This retrospective study compares the reconstitution of T, B and NK cells in three groups of patients transplanted for haematological malignancies with grafts from their HLAidentical sibling donors. In all, 15 patients received PBSC after a nonmyeloablative conditioning regimen consisting of fludarabine and 200 cGy TBI, 13 patients received PBSC after myeloablative conditioning and 37 patients received BM after myeloablative conditioning. In the nonmyeloablative group, the NK cells normalised after 1 month, the CD8+ T cells normalised after 3 months, the CD4+ T cells reached near normal values after 9 months and the B cell values were reduced until 12 months after transplant. In the two myeloablative groups, recipients of PBSC had a significantly higher number of CD4+ T cells after 4 months (P ¼ 0.004) and after 12 months (P ¼ 0.001), than recipients of BM. We found no differences in the T cell reconstitution between the two PBSC groups. This was of interest as the recipients of nonmyeloablative conditioning were older (Po0.001) and had a higher occurrence of chronic GVHD (Po0.05) than the recipients of myeloablative conditioning. In contrast, the recipients of nonmyeloablative conditioning had a delayed B cell recovery when compared to the patients who received myeloablative conditioning (P ¼ 0.04). Bone Marrow Transplantation (2003) 32, 65-72. doi:10.1038/sj.bmt.1704084 Keywords: immune reconstitution; nonmyeloablative conditioning regimen; peripheral blood stem cell transplantation Allogeneic haematopoietic stem cell transplantation after nonmyeloablative conditioning is a treatment modality increasingly used for patients with haematological malignancies ineligible for conventional myeloablative BMT because of older age, comorbidity or the high treatmentrelated mortality after conventional BMT in particular diseases. The results of nonmyeloablative stem cell transplantation have so far been promising. 1, 2 One advantage of the use of a nonmyeloablative conditioning regimen is the brief granulo-and thrombocytopenia, which allows the procedure to be performed in an outpatient setting. The reconstitution of the T, B and NK cells after stem cell transplantation is however also important for the defence against pathogens, 3 and low counts of CD4+ T cells and of B cells have been associated with an increased risk of infection. 4, 5 Thymic function is impaired after conventional haematopoietic stem cell transplantation, and this is partially because of the high-dose radiochemotherapy included in the conditioning regimen. 6 As the thymic activity post-transplant has been shown to be important for the generation of a diverse and efficient T cell response, 7, 8 the lower toxicity of a nonmyeloablative conditioning regimen could in theory enhance the T cell reconstitution. In this study, we retrospectively compared the reconstitution of absolute numbers of T, B and NK cells in patients transplanted with PBSC and conditioned with a nonmyeloablative regimen to patients who received conventional myeloablative conditioning and PBSC or BM. Multiple linear logistic regression analysis was performed to identify factors with possible influence on the lymphoid reconstitution.
Patients and methods

Patients
A total of 76 consecutive patients were transplanted with stem cells from their HLA-identical sibling donors between January 1997 and September 2001. Of these, 15 patients were conditioned with a nonmyeloablative regimen and transplanted with PBSC, while 61 patients were conditioned with a conventional myeloablative regimen and transplanted with PBSC (16 patients) or BM (45 patients). In the two groups transplanted with myeloablative regimens, no information was available about immune reconstitution in three patients in the PBSC group and in eight patients in the BM group. These patients were therefore excluded from the study.
Donors
The donors in the nonmyeloablative PBSC group received filgrastim 16 mg/kg/day for 5 days. Leukapheresis was performed on days 4 and 5 and both leukapheresis products were given to the patient. The donors in the conventional PBSC group received filgrastim 10 mg/kg/day for 5 or 6 days. Leukapheresis was performed on day 5 and if less than 5 Â 10 6 CD34+ cells per kilogram recipient weight were acquired, a second leukapheresis was performed on day 6. All leukaphereses were performed with the COBE Spectra apheresis system (COBE Laboratories, Zaventem, Belgium). The BM was collected according to standard procedures with a target of 3 Â 10 8 nucleated cells per kilogram recipient weight.
HLA typing
HLA typing for HLA-A, -B, -C was performed with the standard microcytotoxicity assay. 9 HLA-DR genotyping was performed by sequence-specific primer polymerase chain reaction (Dynal, Oslo, Norway). 10 
Preparative regimens
The nonmyeloablative conditioning regimen used was developed at The Fred Hutchinson Cancer Research Center 1 and consisted of 200 cGy of TBI at day 0 (two patients) or fludarabine 30 mg/m 2 once daily i.v. at day -4 to day -2 (total dose 90 mg/m 2 ) and 200 cGy of TBI at day 0 (13 patients). Oral cyclosporine 12.5 mg/kg/day was initiated at day -3 and tapered from day 35 in the absence of GVHD in 10 patients or from day 56 in five patients. Oral mycophenolate mofetil 30 mg/kg/day was initiated on day 0 and continued until day 27 in all patients. The patients in the two conventional conditioning groups received cyclophosphamide 60 mg/kg once daily i.v. for two consecutive days (total dose 120 mg/kg) and either 1200 cGy of TBI in three fractions or oral busulphan 4 mg/ kg in divided doses daily for 4 days (total dose 16 mg/kg). One patient in the BM group received cyclophosphamide and antithymocyte globulin 20 mg/kg once daily i.v. for 3 days (total dose 60 mg/kg). In all patients receiving conventional conditioning, the GVHD prophylaxis consisted of methotrexate 15 mg/m 2 on day +1 and 10 mg/m 2 on days +3, +6 and +11 together with cyclosporine which was continued to day 180.
Graft composition
In all grafts, the total nucleated cell number (TNCN) was counted with a Beckman Coulter Z1 cell and particle 
GVHD
The occurrence of acute and chronic GVHD was determined according to standard criteria. 11 Patients were scored for chronic GVHD on day +100 and censored at death.
Quantification of lymphocyte subsets
TruCOUNT Tubes and monoclonal antibodies (Becton Dickinson Immunocytometry Systems) were used to quantify the absolute numbers of helper T cells (CD3+, CD4+, CD8À), cytotoxic T cells (CD3+, CD8+, CD4À), B cells (CD19+, CD20+) and NK cells (CD16+CD56+, CD3À) in EDTA anticoagulated peripheral blood. The samples were analysed by three-colour flow cytometry with Coulter system II software on a Coulter-Epics-XL-MCL flow cytometer (Beckman Coulter). A total of 5000 beads were analysed in each sample. Quantification of lymphocyte subsets was performed on days -7, +7, +14, +21, +28, +42, +56, +90, +120, +180, +270 and +365 days in the nonmyeloablative group and on days +120 and +365 in the two conventional groups. The B cell counts in the patients with CLL were omitted from the analysis as long as monoclonal B cells could be detected. In the donors, the lymphocyte subset numbers were examined before G-CSF stimulation in 12 of the 15 donors in the nonmyeloablative group, in 11 of the 13 donors in the conventional PBSC group and in 28 of the 37 donors in the conventional BM group. The results were pooled and used as reference values for the analysis of the lymphoid reconstitution of the patients.
Statistical methods
The Kruskal-Wallis test was used to compare continuous variables in the three groups of patients and donors. Categorical variables were compared with Fishers exact test. The occurrence of acute and chronic GVHD in the three groups was compared with the logrank test. Multiple linear logistic regression was used to determine factors with possible influence on the lymphoid immune reconstitution. Above or pmedian number of T, B and NK cells at 120 and 365 days were used as dependent variables. Patient's age, donor's age and transfused total nucleated cell number were included as continuous explanatory variables. NonHodgkin's lymphoma (NHL), CLL, AML, CML, multiple myeloma, mode of transplant, acute GVHD grade II-IV and the presence of chronic GVHD before 120 or 365 days were included as categorical explanatory variables. The explanatory variables were included into the model by stepwise selection. SAS software version 8.02 (SAS Institute Inc., Cary, NC, USA) was used for all calculations except for the logrank test where GraphPad Prism version 3.00 (GraphPad Software, San Diego, CA, USA) was used. A P-value of o0.05 was considered significant.
Results
Patient and donor characteristics
The patients and donors in the two conventional BMT groups did not differ in age, but both the patients and donors in the nonmyeloablative BMT group were significantly older than in the two conventional groups (Table 1) . This reflects the criteria currently used for assignment of patients to a nonmyeloablative transplantation regimen. There were great differences in the diagnoses in the three groups. There was a higher proportion of patients with NHL in the nonmyeloablative group, because the criteria used for assignment of patients to this regimen at our institution, where NHL is generally not considered an indication for conventional stem cell transplantation. The differences in diagnoses in the two conventional groups with a higher proportion of patients with CML in the BM group, and a higher proportion of patients with AML in the PBSC group is because of our institutional policy of preferential use of marrow grafts for patients with CML in first chronic phase and patients with severe aplastic anaemia and PBSC grafts for patients with other diagnoses. The two groups of patients transplanted with PBSC received significantly higher numbers of nucleated cells than the patients transplanted with BM. There were however no differences in the total number of cells, or the number of CD34+ cells between the two PBSC groups ( Table 1) . Examination of the lymphocyte subsets in the donors before they received G-CSF stimulation did not reveal any differences except for the CD8+ T cells, where the donors in the conventional PBSC transplant group had higher counts than the two other groups (Table 1) 
GVHD
There was no significant difference in the cumulative incidence of acute GVHD grade II-IV (Figure 1a ). There was a significantly higher occurrence of chronic GVHD in the nonmyeloablative group when compared to the conventional PBSC group, P ¼ 0.049 and when compared to the BM group P ¼ 0.041 (Figure 1b) .
T cell reconstitution
The counts of CD4+ T cells in the patients transplanted with a nonmyeloablative conditioning regimen were below normal values until 9 months after transplant in the (Figure 2c ). T cell reconstitution was compared between the three groups of patients at days +120 and +365. There were no significant differences between the two groups transplanted with PBSC (Figure 3a and b) . The counts of CD4+ T cells in the conventional PBSC group were higher than in the BM group both on day +120 (P ¼ 0.004) and on day +365 (P ¼ 0.001), and there was a trend towards higher counts in the nonmyeloablative PBSC group when compared to the BM group on day +120 (P ¼ 0.06) and on day +365 (P ¼ 0.09) (Figure 3a ). In the CD8+ T cell compartment no significant differences were observed (Figure 3b) .
B-and NK-cell reconstitution
In the patients treated with nonmyeloablative conditioning the B cell counts were reduced in most patients until 9-12 months after transplant (Figure 4a ). In the NK-cell compartment, the counts rapidly increased to near normal values 28 days after transplant, then declined with a nadir around day 56 followed by normalisation 3 months posttransplant (Figure 4b ). In the comparison with the two conventional groups, the B cell counts were significantly reduced in the nonmyeloablative group at 120 days posttransplant (P ¼ 0.04) whereas there were no differences 365 days post-transplant (Figure 5a ). There were no differences in the reconstitution of NK cells between the three groups ( Figure 5b ).
Multiple linear logistic regression analysis
Factors of possible relevance for the lymphoid immune reconstitution were chosen as explanatory variables (see statistical methods). The diagnoses likely to have a confounding effect on the comparison between the three groups of patients were identified as those with a P-value of o0.1 in Table 1 . Three factors could be identified as having significant effects on the numbers of lymphoid cells posttransplant ( Table 2 ). The source of the graft strongly affected the CD4+ T cell reconstitution at 4 and 12 months, with PBSC being superior to BM. This effect was not seen in the other cell populations. Acute GVHD negatively affected B cell reconstitution at 4 months but seemed to have a positive effect on CD8+ T cell counts at 4 and 12 months. Increasing patient age had a slightly negative effect on the B cell reconstitution at 4 months, and a slightly positive effect on CD4+ T cell numbers at 12 months. Chronic GVHD, underlying disease or nonmyeloablative transplant regimen did not have significant effects in this analysis.
Discussion
Infections remain a significant problem after haematopoietic stem cell transplantation and are a major cause of nonrelapse morbidity and mortality. It is therefore important to explore ways to accelerate immune reconstitution. In HLA-identical sibling transplants, PBSC grafts have previously been shown to improve the immune reconstitution and lower the rate of infections. 12, 13 In murine models and human in vitro systems, administration of IL-7 has been shown to improve thymic function and enhance the T cell generation. [14] [15] [16] Another agent with potential clinical use is keratinocyte growth factor that has been shown to protect the thymic epithelia from damage by radiochemotherapy, and to enhance T cell reconstitution in a murine model of BMT. 17 These approaches show that immune reconstitution is a dynamic process that can potentially be manipulated. In the present study, we have found that in patients transplanted with unmanipulated PBSC grafts from HLA-identical sibling donors there were no differences in the kinetics of reconstitution of the counts of CD4+ T, CD8+ T and NK cells, between the patients conditioned with a nonmyeloablative or a myeloablative regimen. The time to reconstitution of the T, B and NK cells in the recipients of nonmyeloablative conditioning was not different from previous reports on immune reconstitution in recipients of conventional myeloablative PBSC transplants from HLA-identical sibling donors. 13, 18 The rather high occurrence of chronic GVHD in recipients of nonmyeloablative conditioning has also been reported earlier 1, 19 and remains a significant cause of morbidity in these patients.
The multiple linear regression analysis performed in this study suggests that acute GVHD grade II-IV and/or its treatment and older patient age inhibited B cell reconstitution. This may explain the delayed recovery of B cells in the recipients of nonmyeloablative conditioning, as they were older and had a higher cumulative incidence of acute GVHD (50%) than the patients in the two conventional transplant groups (35-40%) although this difference was not significant (Figure 1 ). Both acute and chronic GVHD and/or its treatment have previously been shown to inhibit B lymphopoiesis, 20 but in that study age did not have an inhibitory effect. In another study, 21 chronic GVHD inhibited B cell reconstitution and was also a risk factor for low IgG levels, whereas patient age was a risk factor for low IgA levels. Impaired B cell function in patients with chronic GVHD has been described previously. 3, 22 Age has been shown to correlate negatively with reconstitution of CD4+ T cells 23 and thymic function. 24 The result in our study that an increase in age improved the CD4+ T cell counts 12 months post-transplant is unexpected. Likewise, in our material the occurrence of acute GVHD seems to increase the CD8+ T cell number for at least 12 months post-transplant. Neither correlation has been reported earlier and both need further confirmation. A correlation between increased counts of CD8+ T cells early after transplant and acute GVHD has however been described previously 25 and both chronic GVHD 26 and/or CMV infection 21 may also increase CD8+ T cell numbers. The reconstitution of lymphocyte numbers after nonmyeloablative allogeneic stem cell transplantation has been addressed by several groups. [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] There is however great heterogeneity in these studies with respect to conditioning regimens, graft composition, donor type and postgrafting immunosuppression, and only a few studies compare immune reconstitution in patients treated with the same type of graft and conditioned with either a myeloablative or a nonmyeloablative regimen. Busca et al 33 have reported that the lymphocyte reconstitution after a PBSC transplant was comparable in patients receiving either a myeloablative regimen or a nonmyeloablative regimen. Similar to our results they found decreased numbers of B cells and CD4+ T cells for up to 1 year after transplant in both groups of patients, whereas normal levels of CD8+ T cells were reached after 2-3 months. In a study of transplantation with grafts from matched unrelated donors 31 a faster reconstitution of the diversity of the T cell receptor repertoire was found after nonmyeloablative conditioning when compared to myeloablative conditioning. The reconstitution of the absolute numbers of T cells did not differ in the two groups, and the faster T cell repertoire reconstitution occurred both in recipients of BM and PBSCT. This led to the conclusion that the source of the graft did not influence reconstitution of the complexity of the T cell repertoire after nonmyeloablative conditioning. Chao et al 39 found that both peripheral expansion of the donor T cells and thymus-dependent T cell regeneration was augmented in recipients of mismatched unrelated cord blood when a nonmyeloablative conditioning regimen was used, and as a result the absolute numbers of T cells reconstituted faster and the T cell receptor repertoire became more diverse in these patients. This finding supports the hypothesis that a less toxic conditioning regimen decreases thymic damage and leads to a faster reconstitution of the T cell compartment. The comparable rate of reconstitution of CD4+ T cells in the two PBSC groups in our study could favour this hypothesis as the patients who received nonmyeloablative conditioning had a median age of 51 years and an incidence of chronic GVHD around 80% compared to a median age of 35 years and an incidence of chronic GVHD of 40% in the patients who received myeloablative conditioning. The fact that we did not find a faster reconstitution in the patients who received nonmyeloablative conditioning, does not rule out that the possibility there may be a difference in the reconstitution of subpopulations of T cells or in the reconstitution of the T cell receptor diversity that depends on the mode of conditioning. A study of the T cell receptor diversity following nonmyeloablative conditioning in HLA-identical sibling transplants is in progress in our laboratory.
Interestingly, we found a very rapid increase in the CD4 : CD8 ratio 1 week after transplant in the recipients of nonmyeloablative conditioning. To our knowledge only Bahceci et al 30 have reported measurements of T-lymphocyte reconstitution in the first month after transplant in recipients of nonmyeloablative conditioning, but the CD4 : CD8 ratio was not mentioned. In myeloablative BM transplantation, the CD4 : CD8 ratio is usually inverted in the first months post-transplant. 12, 22, 40 In contrast, in myeloablative PBCS transplantation this inversion does not occur 12, 41, 42 but values as high as we have seen have not been reported. As the CD4 : CD8 ratio in the patients before transplants was low and the CD4 : CD8 ratio in PBSC leukapheresis products is reported to be around 1.2, 43, 44 there must be a preferential proliferation of CD4+ T cells in the first week posttransplant, or a preferential displacement of CD4+ T cells from the lymphoid organs to the intravascular compartment.
In conclusion, our results indicate a similar rate of T cell reconstitution in patients conditioned with a nonmyeloablative regimen or with a conventional myeloablative regimen, provided transplantation with PBSC. Considering the older age and the higher rate of chronic GVHD in the nonmyeloablative transplant cohort, this may indicate an advantage in favour of nonmyeloablative conditioning.
